Quoin Pharmaceuticals更新产品组合

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East.

QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data

Topical Rapamycin Development Programs Advancing Using Two Proprietary Delivery Technologies